Up 92% in a year! Is my biggest winner my best share to buy for 2025 too?

Harvey Jones got it spot on when he decided insurer Just Group was the best share to buy this time last year. Does it still look set fair for the year ahead?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Businessman using pen drawing line for increasing arrow from 2024 to 2025

Image source: Getty Images

On 30 November last year, I decided FTSE 250 financial services advisor Just Group (LSE: JUST) was the best share to buy for my portfolio. And I was right. It had soared 92.57% since then, more than any other stock I hold.

Just has a laser-like focus on later life and retirement income, selling products such as annuities and equity release lifetime mortgages. I thought it should do well as the population ages and grasps the importance of these things.

Just Group is my best stock in 2024

Three days before I parted with my cash, I wrote this on the Fool: “Just has a much narrower product focus than FTSE 100 equivalents such as Aviva and Legal & General Group, which has made it more turbulent”.

In 2018, Just shares took a beating after the Prudential Regulation Authority (PRA) introduced new rules for calculating capital reserves for companies offering annuities. This forced Just to raise additional capital, spooking investors who feared dilution.

The shares plunged and continued to idle once the issue was resolved. JP Morgan was awake to the opportunity, noting that Just is “clearly punching above its weight” in the fast-growing UK pension risk transfer market, where it has a 10% share. It also benefited from the annuity resurgence, as interest rates handed retirees a better return.

I should add a disclaimer here. When I’m not writing for The Motley Fool, I’m a personal finance journalist, so I know the Just PR team. That applies to a heap of financial firms though and I wouldn’t gamble my retirement pot on them for that reason.

This stock could smash it in 2025 too

I invested because I thought the shares looked ridiculously under-valued trading at what I called “a rock bottom valuation of just 4.24 times earnings”. The price-to-book ratio was a mere 0.4. This seemed plain wrong for a company that had just doubled first-half sales to more than £1.9bn. So I swooped.

Over 12 months, Just’s shares are up 85.66%. Yet the shares still look incredibly cheap, trading at 5.57 times earnings.

Last month, Just announced its biggest ever bulk annuity deal, a £1.8bn full buy-in with the G4S Pension Scheme, covering 22,500 members. On 19 November, JP Morgan reiterated its Overweight rating and lifted the price target from 190p to 200p. Today, the shares trade at 159.9p. That suggests another 25% of potential upside.

One thing worries me. When interest rates fall, the boom in personal annuities could deflate, hitting profits. As a smaller player, that would hit Just more than Aviva or L&G. Investors are optimistic today but that can change in a moment.

By contrast to other insurers, the yield isn’t much to shout about at 1.31%. That’s partly down to its rocketing share price though, as management is progressive.

If I didn’t hold Just Group I would buy it. I expect another positive year in 2025, although nothing to match what we’ve just seen. I’ve got enough exposure now, thanks to the strong run, and will look elsewhere for next year’s big winner.

Harvey Jones has positions in Just Group Plc and Legal & General Group Plc. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Middle-aged white man pulling an aggrieved face while looking at a screen
Market Movers

Down 7%! Why on earth are Imperial Brands shares plummeting today?

Imperial Brands shares are in freefall after a negative reception to fresh trading news. Is the party finally over for…

Read more »

Rear View Of Woman Holding Man Hand during travel in cappadocia
Investing Articles

With a P/E under 7, this value stock looks far too cheap at 101p

This writer reckons value stock Hostelworld (LSE:HSW) looks dirt-cheap as it gets dividends flowing again and builds a social travel…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Investing For Beginners

Down 30% in 6 months, I think there’s a big catch to this insanely cheap stock

Jon Smith talks through why careful research is needed when trying to assess if a cheap stock is worth buying…

Read more »

Investing Articles

£5,000 invested in National Grid shares 5 years ago is now worth…

Andrew Mackie takes a closer look at National Grid shares and why short-term market weakness could be missing a powerful…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

How big does an ISA need to be to aim for a £1,500 monthly second income?

Harvey Jones shows how building a balanced portfolio of FTSE 100 dividend stocks can produce a high-and-rising second income in…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

A 6.8% forecast yield! 1 often-overlooked FTSE 100 income stock to buy today?

This income stock offers a high forecast yield and strengthening momentum, yet many investors overlook it — creating a rare…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »